Aurobindo’s tally of USFDA approved cephs goes up

16108 Investors following Aurobindo Pharm. Share this News with them.

0

Like this story, share it with millions of investors on M3

Aurobindo’s tally of USFDA approved cephs goes up

Aurobindo’s tally of USFDA approved cephs goes up

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Aurobindo receives USFDA nod for its facility at UNIT-VI Aurobindo Pharma: Good growth in US, EU Aurobindo Pharma Q3 net surges to Rs 60.1cr Aurobindo Pharma’s net Profit grew by 130% ALSO READ See latest News about Aurobindo Pharm See previous management interviews See what other Experts & Brokerages are saying about Aurobindo Pharm Aurobindo Pharm BSE | NSE 25/05/12 Are Mutual Funds betting on Aurobindo Pharm?

Aurobindo is pleased to announce that US FDA has approved one more Cephalosporin, cefprozil oral suspension 125mgml, 250mgml from its range.

Cefprozil is a second generation cephalosporin antibiotic and is a generic version of the brand Cefzil marketed by Bristol Myers Squibb of USA. Cefprozil is widely used in upper; lower respiratory tract infections, skin & soft tissue infections. This is the fourth cephalosporin and 38th product of Aurobindo receiving USFDA approval. Cefprozil enjoys a market of over 100-mio dollars in the USA.

Sourced From: Aurobindo Pharma Limited